• In early May 2026, Denali Therapeutics announced that partner Takeda will terminate their collaboration on DNL593 for strategic reasons unrelated to efficacy or safety, returning full development and commercialization rights to Denali.
• This shift gives Denali complete control over DNL593 and its underlying TransportVehicle technology, which it expects to further highlight with planned phase I/II data by the end of 2026.
• We will now examine how Denali regaining full rights to DNL593 could influence the company’s longer-term investment narrative and risk profile.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Denali Therapeutics' Investment Narrative?

To own Denali Therapeutics, you really have to believe in its blood brain barrier TransportVehicle platform translating into meaningful medicines, with AVLAYAH’s recent accelerated approval as the first proof of concept. The near term story still hinges on execution in Hunter syndrome and broader pipeline progress, while the balance sheet funds sizeable R&D but also underlines how dependent the company is on external validation. Takeda’s decision to exit DNL593 shifts that balance a bit: it removes a big pharma backer on one asset, but hands Denali full upside and control just ahead of key phase I/II data planned for late 2026. With shares weak in the short term yet still pricing in ambitious growth, the core risks remain execution, trial outcomes and continued cash burn, now with one less partner sharing the load.

However, investors should be aware of how sustained losses could pressure Denali if catalysts slip. According our valuation report, there's an indication that Denali Therapeutics' share price might be on the expensive side.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community cluster around US$33.72 to US$35.64, yet recent Takeda news and Denali’s ongoing cash losses remind you that opinions and outcomes can diverge sharply.

Explore 2 other fair value estimates on Denali Therapeutics - why the stock might be worth just $33.72!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Denali Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Denali Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Denali Therapeutics' overall financial health at a glance.

Interested In Other Possibilities?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.